Matthew K Fust

Director · 5 filings · Latest: Sep 1, 2026

Atara Biotherapeutics, Inc.

Crinetics Pharmaceuticals, Inc.

Neumora Therapeutics, Inc.

Ultragenyx Pharmaceutical Inc.

Ticker	Owner	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Filing
CRNX	MATTHEW K FUST	—	Sep 26, 2025	Proposed Sale	$35.89	16,000	$574.2K	—	Sep 26 8:27 PM
NMRA	Fust Matthew K	—	Oct 18, 2024	Proposed Sale	$17.03	14,049	$239.3K	—	Oct 18 8:01 PM
NMRA	Fust Matthew K	—	Oct 17, 2024	Proposed Sale	$17.01	7,739	$131.6K	—	Oct 17 8:26 PM